Michael J Dunn1, Simon Killcross. 1. Centre for Psychology, University of Wales Institute, Cardiff Western Avenue, Cardiff, CF5 2YB, UK. mdunn@uwic.ac.uk
Abstract
RATIONALE: Recent experimental findings suggest that a core cognitive deficit of schizophrenia is the degraded ability to use task-setting cues to guide goal-directed behaviour, that this deficit is evident in acute as well as chronic schizophrenia, and that such deficits can me modelled in animals using conditional discrimination tasks. OBJECTIVE: To establish the reversal potential of D1, D2 and 5-HT receptor antagonists acutely, and D1 and D2 receptor antagonists chronically, on d-amphetamine-induced disruption of a conditional discrimination task that depends on the ability to use task-setting cues to direct goal directed performance. METHOD: A conditional discrimination paradigm was employed in which rats learned to respond on an appropriate lever, conditional upon specific auditory stimuli. RESULTS: d-Amphetamine (1.5 mg/kg) disruption of conditional discrimination was attenuated by acute pre-treatment with the selective D1 antagonist SCH 23390 and the atypical anti-psychotic clozapine (Cloz). Acute pre-treatment with the selective D2 antagonist eticlopride (Eti) and the anti-psychotic haloperidol (Hal) failed to reverse d-amphetamine disruption, as did pre-treatment with the selective 5HT1A antagonist WAY 100635 and the selective 5HT2A/C antagonist ritanserin. However, Eti and Hal did reverse d-amphetamine-induced task disruption when administered chronically (as did SCH 23390, alpha-flupenthixol and Cloz). CONCLUSIONS: These results suggest that D1 receptors are involved in tasks that require the use of conditional relationships and that D2 receptor antagonism can come to exert a similar influence after chronic treatment.
RATIONALE: Recent experimental findings suggest that a core cognitive deficit of schizophrenia is the degraded ability to use task-setting cues to guide goal-directed behaviour, that this deficit is evident in acute as well as chronic schizophrenia, and that such deficits can me modelled in animals using conditional discrimination tasks. OBJECTIVE: To establish the reversal potential of D1, D2 and 5-HT receptor antagonists acutely, and D1 and D2 receptor antagonists chronically, on d-amphetamine-induced disruption of a conditional discrimination task that depends on the ability to use task-setting cues to direct goal directed performance. METHOD: A conditional discrimination paradigm was employed in which rats learned to respond on an appropriate lever, conditional upon specific auditory stimuli. RESULTS:d-Amphetamine (1.5 mg/kg) disruption of conditional discrimination was attenuated by acute pre-treatment with the selective D1 antagonist SCH 23390 and the atypical anti-psychotic clozapine (Cloz). Acute pre-treatment with the selective D2 antagonist eticlopride (Eti) and the anti-psychotic haloperidol (Hal) failed to reverse d-amphetamine disruption, as did pre-treatment with the selective 5HT1A antagonist WAY 100635 and the selective 5HT2A/C antagonist ritanserin. However, Eti and Hal did reverse d-amphetamine-induced task disruption when administered chronically (as did SCH 23390, alpha-flupenthixol and Cloz). CONCLUSIONS: These results suggest that D1 receptors are involved in tasks that require the use of conditional relationships and that D2 receptor antagonism can come to exert a similar influence after chronic treatment.
Authors: M Laruelle; G E Jaskiw; B K Lipska; B Kolachana; M F Casanova; J E Kleinman; D R Weinberger Journal: Brain Res Date: 1992-03-13 Impact factor: 3.252
Authors: J Karle; L Clemmesen; L Hansen; M Andersen; J Andersen; C Fensbo; M Sloth-Nielsen; B K Skrumsager; H Lublin; J Gerlach Journal: Psychopharmacology (Berl) Date: 1995-10 Impact factor: 4.530
Authors: Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru Journal: Nature Date: 1997-02-13 Impact factor: 49.962
Authors: Sophie Dix; Gary Gilmour; Slavinka Potts; Janice W Smith; Mark Tricklebank Journal: Psychopharmacology (Berl) Date: 2010-07-31 Impact factor: 4.530
Authors: Cathalijn H C Leenaars; Ruud N J M A Joosten; Allard Zwart; Hans Sandberg; Emma Ruimschotel; Maaike A J Hanegraaf; Maurice Dematteis; Matthijs G P Feenstra; Eus J W van Someren Journal: Sleep Date: 2012-02-01 Impact factor: 5.849
Authors: Andrea Bari; Adam C Mar; David E Theobald; Sophie A Elands; Kelechi C N A Oganya; Dawn M Eagle; Trevor W Robbins Journal: J Neurosci Date: 2011-06-22 Impact factor: 6.167
Authors: Fuat Balci; Elliot A Ludvig; Jacqueline M Gibson; Brian D Allen; Krystal M Frank; Bryan J Kapustinski; Thomas E Fedolak; Daniela Brunner Journal: Psychopharmacology (Berl) Date: 2008-07-23 Impact factor: 4.530
Authors: D Feifel; S Mexal; Gilia Melendez; Philip Y T Liu; Joseph R Goldenberg; Paul D Shilling Journal: Neuropsychopharmacology Date: 2009-03-25 Impact factor: 7.853